文献速递主动脉疾病

EVAR术后内漏转归及口服抗凝对持续内漏的影响

The fate of endoleaks after endovascular aneurysm repair and the impact of oral anticoagulation on their persistence.
PubMed 文献 · J Vasc Surg · 2021-05-01

基于VQI数据库2003–2019年29,783例腹主动脉瘤EVAR患者,2169例(7.3%)出现晚期内漏。EVAR前后抗凝者晚期内漏风险显著升高(OR 4.23),EVAR后抗凝OR 1.88,索引内漏OR 1.45;华法林与新型口服抗凝药间无差异。

要点

  • EVAR前后均抗凝者晚期内漏风险最高(OR 4.23)。
  • 华法林与新型口服抗凝药对晚期内漏的影响无差异。
  • 索引内漏合并EVAR后抗凝者晚期内漏频率达20.42%。

核心结论

  • EVAR后接受抗凝治疗的患者晚期内漏更常见。
  • 华法林与新型口服抗凝药在晚期内漏频率上无差异。
  • 抗凝患者及存在索引内漏者发生晚期内漏的风险更高。

研究设计与样本

  • 使用血管外科学会血管质量倡议(VQI)数据库,纳入2003–2019年因腹主动脉瘤行EVAR的患者。
  • 共分析29,783例患者,分为无晚期内漏组与有晚期内漏组。
  • 采用双变量分析评估围术期及随访变量,多变量分析确定与晚期内漏相关的独立变量。

主要发现

  • 29,783例中2169例(7.3%)发现晚期内漏。
  • EVAR前后均抗凝者晚期内漏频率为16.89%,仅EVAR后抗凝者为14.40%,从未抗凝者为6.95%(两者P均>.001)。
  • 索引内漏合并EVAR后抗凝者晚期内漏频率为20.42%,仅EVAR后抗凝者为14.63%(P=.0015),索引内漏未抗凝者为10.06%(P<.00001)。
  • 最常见的索引内漏和晚期内漏类型均为II型,且I、II、IV型索引内漏患者分别更常见对应类型的晚期内漏。

关键数值与推荐

  • EVAR前后均抗凝与晚期内漏的OR为4.23(95%CI 2.57-6.96,P<.001)。
  • EVAR后抗凝与晚期内漏的OR为1.88(95%CI 1.43-2.49,P<.001)。
  • 索引内漏与晚期内漏的OR为1.45(95%CI 1.26-1.66,P<.001)。

临床怎么用

  • 对EVAR术后接受抗凝治疗的患者应加强内漏监测。
  • 存在索引内漏且术后抗凝的患者晚期内漏风险最高,需密切随访。
  • 选择华法林或新型口服抗凝药时,晚期内漏风险无差异可供参考。

局限性

  • 原文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The impact of anticoagulation on late endoleaks after endovascular aneurysm repair (EVAR) is unclear despite multiple investigators studying the relationship. The purpose of this study was to determine if long-term anticoagulation impacted the development of late endoleaks and if specific anticoagulants were more likely to exacerbate the development of endoleaks. METHODS: Using the Society for Vascular Surgery Vascular Quality Initiative database, patients undergoing EVAR between 2003 and 2019 for abdominal aortic aneurysms were evaluated. Patients were divided into two groups: those without a late endoleak and those with a late endoleak. Bivariate analysis was performed to assess preoperative, intraoperative, postoperative, and long-term follow-up variables. A multivariable analysis was done to determine associations of independent variables with late endoleaks. Patients were further subcategorized based on anticoagulation status before and after EVAR, specific type of anticoagulation, and the presence of an index endoleaks (diagnosed at the time of EVAR) to determine the subsequent frequency of late endoleaks. RESULTS: A total of 29,783 patients were analyzed with 2169 (7.3%) having a late endoleak identified. Several risk factors were related to late endoleaks, including anticoagulation before and after EVAR (odds ratio [OR], 4.23; 95% confidence interval [CI], 2.57-6.96; P < .001), anticoagulation after EVAR (OR, 1.88; 95% CI, 1.43-2.49; P < .001), and index endoleak (OR, 1.45; 95% CI, 1.26-1.66; P < .001). The frequency of late endoleaks in patients anticoagulated before and after EVAR and after EVAR as compared with those never anticoagulated was 16.89% and 14.40% vs 6.95%, respectively (both P > .001). No difference in late endoleaks were noted for patients treated with warfarin and novel oral anticoagulants. The most common type of index and late endoleak identified was type II, but patients with type I, type II, and type IV index endoleaks were more commonly found to have type I, type II, and type IV late endoleaks, respectively. The frequency of late endoleaks in patients with both an index endoleak and anticoagulation after EVAR was 20.42% as compared with patients with only anticoagulation after EVAR (14.63%; P = .0015) and with patients with index endoleaks not anticoagulated (10.06%; P < .00001). CONCLUSIONS: Late endoleaks were more common in patients treated with anticoagulation after EVAR. No difference in late endoleak frequency was detected between anticoagulation with warfarin and novel oral anticoagulants. Patients on anticoagulation and those with an index endoleak were at a higher risk of having a late endoleak.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Flohr TR, Snow R, Aziz F, et al. The fate of endoleaks after endovascular aneurysm repair and the impact of oral anticoagulation on their persistence. J Vasc Surg. 2021. PMID: 33940069. doi:10.1016/j.jvs.2021.04.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。